These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 16686722

  • 1. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
    Staskin DR, Te AE.
    BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A, Wyndaele JJ, Sieber P.
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [Abstract] [Full Text] [Related]

  • 3. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
    Haab F, Cardozo L, Chapple C, Ridder AM, Solifenacin Study Group.
    Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
    [Abstract] [Full Text] [Related]

  • 4. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD, Lucente V, Vapnek J, Smith N.
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
    Millard RJ, Halaska M.
    Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429
    [Abstract] [Full Text] [Related]

  • 7. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M.
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M, Japanese Solifenacin Study Group.
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [Abstract] [Full Text] [Related]

  • 9. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J, SUNRISE Study Group.
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [Abstract] [Full Text] [Related]

  • 10. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP, Laramée C, Lucente V, Fakhoury A, Forero-Schwanhaeuser S.
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [Abstract] [Full Text] [Related]

  • 11. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
    Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM.
    BJU Int; 2005 Jan; 95(1):81-5. PubMed ID: 15638900
    [Abstract] [Full Text] [Related]

  • 12. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W.
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [Abstract] [Full Text] [Related]

  • 13. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
    Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S.
    Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
    [Abstract] [Full Text] [Related]

  • 14. Redefining response in overactive bladder syndrome.
    Payne CK, Kelleher C.
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [Abstract] [Full Text] [Related]

  • 15. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
    Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, Mistry A, Wright DM, Bolodeoku J, STAR study group.
    Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
    [Abstract] [Full Text] [Related]

  • 16. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
    Wong C, Duggan P.
    J Obstet Gynaecol; 2009 Jan; 29(1):31-4. PubMed ID: 19280492
    [Abstract] [Full Text] [Related]

  • 17. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colón R.
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [Abstract] [Full Text] [Related]

  • 18. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
    Toglia MR, Serels SR, Laramée C, Karram MM, Nandy IM, Andoh M, Seifeldin R, Forero-Schwanhaeuser S.
    Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
    [Abstract] [Full Text] [Related]

  • 19. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.
    Abrams P, Swift S.
    Eur Urol; 2005 Sep; 48(3):483-7. PubMed ID: 16005564
    [Abstract] [Full Text] [Related]

  • 20. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.